Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 506

1.

Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression.

López González M, Oosterhoff D, Lindenberg JJ, Milenova I, Lougheed SM, Martiáñez T, Dekker H, Quixabeira DCA, Hangalapura B, Joore J, Piersma SR, Cervera-Carrascon V, Santos JM, Scheper RJ, Verheul HMW, Jiménez CR, Van De Ven R, Hemminki A, Van Beusechem VW, De Gruijl TD.

Oncoimmunology. 2019 Jul 19;8(10):e1631119. doi: 10.1080/2162402X.2019.1631119. eCollection 2019.

2.

Hypertrophic and keloid scars fail to progress from the CD34- /α-smooth muscle actin (α-SMA)+ immature scar phenotype and show gradient differences in α-SMA and p16 expression.

Limandjaja GC, Belien JM, Scheper RJ, Niessen FB, Gibbs S.

Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18219. [Epub ahead of print]

PMID:
31206605
3.

Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM.

Cancer Immunol Immunother. 2019 Jun;68(6):1037. doi: 10.1007/s00262-019-02328-6.

4.

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM.

Cancer Immunol Immunother. 2019 Jun;68(6):1025-1035. doi: 10.1007/s00262-019-02320-0. Epub 2019 Mar 9. Erratum in: Cancer Immunol Immunother. 2019 Mar 27;:.

5.

Reconstructed human keloid models show heterogeneity within keloid scars.

Limandjaja GC, van den Broek LJ, Waaijman T, Breetveld M, Monstrey S, Scheper RJ, Niessen FB, Gibbs S.

Arch Dermatol Res. 2018 Dec;310(10):815-826. doi: 10.1007/s00403-018-1873-1. Epub 2018 Oct 28.

6.

Characterization of In Vitro Reconstructed Human Normotrophic, Hypertrophic, and Keloid Scar Models.

Limandjaja GC, van den Broek LJ, Breetveld M, Waaijman T, Monstrey S, de Boer EM, Scheper RJ, Niessen FB, Gibbs S.

Tissue Eng Part C Methods. 2018 Apr;24(4):242-253. doi: 10.1089/ten.TEC.2017.0464. Epub 2018 Apr 2.

PMID:
29490604
7.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

8.

Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.

Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD.

Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944.

9.

Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.

van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, Scheper RJ, van Leeuwen PAM, van den Tol MP, de Gruijl TD.

Cancer Immunol Res. 2017 Nov;5(11):969-977. doi: 10.1158/2326-6066.CIR-17-0110. Epub 2017 Sep 21.

10.

Comparison of advanced therapy medicinal product gingiva and skin substitutes and their in vitro wound healing potentials.

Boink MA, Roffel S, Breetveld M, Thon M, Haasjes MSP, Waaijman T, Scheper RJ, Blok CS, Gibbs S.

J Tissue Eng Regen Med. 2018 Feb;12(2):e1088-e1097. doi: 10.1002/term.2438. Epub 2017 Jun 22.

11.

Immunostimulatory capacity of dental casting alloys on endotoxin responsiveness.

Rachmawati D, von Blomberg BME, Kleverlaan CJ, Scheper RJ, van Hoogstraten IMW.

J Prosthet Dent. 2017 May;117(5):677-684. doi: 10.1016/j.prosdent.2016.08.013. Epub 2016 Oct 27.

PMID:
27881328
12.

Variation in Host and Pathogen in the Neonectria/Malus Interaction; toward an Understanding of the Genetic Basis of Resistance to European Canker.

Gómez-Cortecero A, Saville RJ, Scheper RW, Bowen JK, Agripino De Medeiros H, Kingsnorth J, Xu X, Harrison RJ.

Front Plant Sci. 2016 Sep 15;7:1365. eCollection 2016.

13.

Increased epidermal thickness and abnormal epidermal differentiation in keloid scars.

Limandjaja GC, van den Broek LJ, Waaijman T, van Veen HA, Everts V, Monstrey S, Scheper RJ, Niessen FB, Gibbs S.

Br J Dermatol. 2017 Jan;176(1):116-126. doi: 10.1111/bjd.14844. Epub 2016 Nov 26.

PMID:
27377288
14.

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.

van den Hout MF, Sluijter BJ, Santegoets SJ, van Leeuwen PA, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Immunother. 2016 Apr;65(4):405-15. doi: 10.1007/s00262-016-1811-z. Epub 2016 Mar 2.

15.

Metal ions potentiate microglia responsiveness to endotoxin.

Rachmawati D, Peferoen LA, Vogel DY, Alsalem IW, Amor S, Bontkes HJ, von Blomberg BM, Scheper RJ, van Hoogstraten IM.

J Neuroimmunol. 2016 Feb 15;291:89-95. doi: 10.1016/j.jneuroim.2015.12.013. Epub 2015 Dec 29.

PMID:
26857501
16.

Draft Genome Sequences of Two Isolates of the Plant-Pathogenic Fungus Neonectria ditissima That Differ in Virulence.

Deng CH, Scheper RW, Thrimawithana AH, Bowen JK.

Genome Announc. 2015 Nov 19;3(6). pii: e01348-15. doi: 10.1128/genomeA.01348-15.

17.

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.

Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DM, Honeywell R, Musters RP, Giovannetti E, O'Toole T, Scheffer GL, Krige D, de Gruijl TD, Niessen HW, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G.

Oncotarget. 2016 Feb 2;7(5):5240-57. doi: 10.18632/oncotarget.6169.

18.

Dental metal-induced innate reactivity in keratinocytes.

Rachmawati D, Buskermolen JK, Scheper RJ, Gibbs S, von Blomberg BM, van Hoogstraten IM.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):325-30. doi: 10.1016/j.tiv.2015.10.003. Epub 2015 Oct 9.

PMID:
26456670
19.

Development of a Full-Thickness Human Skin Equivalent In Vitro Model Derived from TERT-Immortalized Keratinocytes and Fibroblasts.

Reijnders CM, van Lier A, Roffel S, Kramer D, Scheper RJ, Gibbs S.

Tissue Eng Part A. 2015 Sep;21(17-18):2448-59. doi: 10.1089/ten.TEA.2015.0139. Epub 2015 Aug 3.

20.

Continuing the quest for autoimmunity due to oral metal exposure.

Rachmawati D, Muris J, Scheper RJ, Rustemeyer T, Kleverlaan CJ, Feilzer AJ, von Blomberg BM, van Hoogstraten IM.

Autoimmunity. 2015;48(7):494-501. doi: 10.3109/08916934.2015.1033688. Epub 2015 Apr 27.

PMID:
25915572
21.

Proteasome inhibitors as experimental therapeutics of autoimmune diseases.

Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G.

Arthritis Res Ther. 2015 Jan 28;17:17. doi: 10.1186/s13075-015-0529-1. Review.

22.

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.

Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.

23.

Innate stimulatory capacity of high molecular weight transition metals Au (gold) and Hg (mercury).

Rachmawati D, Alsalem IW, Bontkes HJ, Verstege MI, Gibbs S, von Blomberg BM, Scheper RJ, van Hoogstraten IM.

Toxicol In Vitro. 2015 Mar;29(2):363-9. doi: 10.1016/j.tiv.2014.10.010. Epub 2014 Oct 30.

PMID:
25458486
24.

Scientific contributions toward successful cancer immunotherapy in The Netherlands.

Melief CJ, Scheper RJ, de Vries IJ.

Immunol Lett. 2014 Dec;162(2 Pt B):121-6. doi: 10.1016/j.imlet.2014.10.012. Epub 2014 Oct 16. Review.

PMID:
25455598
25.

CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.

Schneiders FL, Prodöhl J, Ruben JM, O'Toole T, Scheper RJ, Bonneville M, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Cancer Immunol Res. 2014 Aug;2(8):732-40. doi: 10.1158/2326-6066.CIR-13-0167. Epub 2014 Apr 21.

26.

Palladium-based dental alloys are associated with oral disease and palladium-induced immune responses.

Muris J, Scheper RJ, Kleverlaan CJ, Rustemeyer T, van Hoogstraten IM, von Blomberg ME, Feilzer AJ.

Contact Dermatitis. 2014 Aug;71(2):82-91. doi: 10.1111/cod.12238. Epub 2014 May 22.

PMID:
24850306
27.

Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma.

Lindenberg JJ, van de Ven R, Oosterhoff D, Sombroek CC, Lougheed SM, Stam AG, Koenen HJ, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Hum Vaccin Immunother. 2014;10(6):1622-32. doi: 10.4161/hv.28548. Epub 2014 Apr 14.

28.

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD.

J Immunother Cancer. 2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3. eCollection 2014.

29.

Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.

van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G.

Scand J Rheumatol. 2014;43(1):9-16. doi: 10.3109/03009742.2013.797490. Epub 2013 Aug 30.

PMID:
23987246
30.

Differential response of human adipose tissue-derived mesenchymal stem cells, dermal fibroblasts, and keratinocytes to burn wound exudates: potential role of skin-specific chemokine CCL27.

van den Broek LJ, Kroeze KL, Waaijman T, Breetveld M, Sampat-Sardjoepersad SC, Niessen FB, Middelkoop E, Scheper RJ, Gibbs S.

Tissue Eng Part A. 2014 Jan;20(1-2):197-209. doi: 10.1089/ten.TEA.2013.0123. Epub 2013 Oct 2.

31.

Autologous skin substitute for hard-to-heal ulcers: retrospective analysis on safety, applicability, and efficacy in an outpatient and hospitalized setting.

Blok CS, Vink L, de Boer EM, van Montfrans C, van den Hoogenband HM, Mooij MC, Gauw SA, Vloemans JA, Bruynzeel I, van Kraan A, Kuik J, Waaijman T, Scheper RJ, Gibbs S.

Wound Repair Regen. 2013 Sep-Oct;21(5):667-76. doi: 10.1111/wrr.12082. Epub 2013 Aug 8. Erratum in: Wound Repair Regen. 2013 Nov-Dec;21(6):909.

PMID:
23926998
32.

IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.

Lindenberg JJ, Oosterhoff D, Sombroek CC, Lougheed SM, Hooijberg E, Stam AG, Santegoets SJ, Tijssen HJ, Buter J, Pinedo HM, van den Eertwegh AJ, Scheper RJ, Koenen HJ, van de Ven R, de Gruijl TD.

PLoS One. 2013 Jul 18;8(7):e70237. doi: 10.1371/journal.pone.0070237. Print 2013.

33.

Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation.

Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJ, Griffioen AW, Hooijberg E, van den Eertwegh AJ, Thijssen VL, Scheper RJ, Oosterhoff D, de Gruijl TD.

Oncoimmunology. 2013 Apr 1;2(4):e23837.

34.

Transition metal sensing by Toll-like receptor-4: next to nickel, cobalt and palladium are potent human dendritic cell stimulators.

Rachmawati D, Bontkes HJ, Verstege MI, Muris J, von Blomberg BM, Scheper RJ, van Hoogstraten IM.

Contact Dermatitis. 2013 Jun;68(6):331-8. doi: 10.1111/cod.12042.

PMID:
23692033
35.

IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.

Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, Powell DJ Jr, June CH, de Gruijl TD.

J Transl Med. 2013 Feb 12;11:37. doi: 10.1186/1479-5876-11-37.

36.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

37.

Development, validation and testing of a human tissue engineered hypertrophic scar model.

van den Broek LJ, Niessen FB, Scheper RJ, Gibbs S.

ALTEX. 2012;29(4):389-402. doi: 10.14573/altex.2012.4.389.

PMID:
23138509
38.

Palladium-induced Th2 cytokine responses reflect skin test reactivity.

Muris J, Feilzer AJ, Kleverlaan CJ, Rustemeyer T, van Hoogstraten IM, Scheper RJ, von Blomberg BM.

Allergy. 2012 Dec;67(12):1605-8. doi: 10.1111/all.12046. Epub 2012 Oct 16.

PMID:
23067003
39.

Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition.

Oosterhoff D, Lougheed S, van de Ven R, Lindenberg J, van Cruijsen H, Hiddingh L, Kroon J, van den Eertwegh AJ, Hangalapura B, Scheper RJ, de Gruijl TD.

Oncoimmunology. 2012 Aug 1;1(5):649-658.

40.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD.

Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.

PMID:
22878899
41.

CCL5 and CCL20 mediate immigration of Langerhans cells into the epidermis of full thickness human skin equivalents.

Ouwehand K, Spiekstra SW, Waaijman T, Breetveld M, Scheper RJ, de Gruijl TD, Gibbs S.

Eur J Cell Biol. 2012 Oct;91(10):765-73. doi: 10.1016/j.ejcb.2012.06.004. Epub 2012 Aug 2.

PMID:
22857950
42.

Simple wound exudate collection method identifies bioactive cytokines and chemokines in (arterio) venous ulcers.

Kroeze KL, Vink L, de Boer EM, Scheper RJ, van Montfrans C, Gibbs S.

Wound Repair Regen. 2012 May-Jun;20(3):294-303. doi: 10.1111/j.1524-475X.2012.00789.x.

PMID:
22564225
43.

Sodium tetrachloropalladate for diagnosing palladium sensitization.

Muris J, Kleverlaan CJ, Rustemeyer T, von Blomberg ME, van Hoogstraten IM, Feilzer AJ, Scheper RJ.

Contact Dermatitis. 2012 Aug;67(2):94-100. doi: 10.1111/j.1600-0536.2012.02061.x. Epub 2012 Mar 30.

PMID:
22462719
44.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
45.

Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up.

Schneiders FL, de Bruin RC, van den Eertwegh AJ, Scheper RJ, Leemans CR, Brakenhoff RH, Langendijk JA, Verheul HM, de Gruijl TD, Molling JW, van der Vliet HJ.

J Clin Oncol. 2012 Feb 10;30(5):567-70. doi: 10.1200/JCO.2011.38.8819. Epub 2012 Jan 17. No abstract available.

PMID:
22253469
46.

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.

Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G.

J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. doi: 10.1124/jpet.111.187542. Epub 2012 Jan 10.

PMID:
22235146
47.

CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.

Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, de Gruijl TD.

J Gene Med. 2012 Jun;14(6):416-27. doi: 10.1002/jgm.1648. Review.

48.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

49.

Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.

Schneiders FL, de Bruin RC, Santegoets SJ, Bonneville M, Scotet E, Scheper RJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2012 Feb;142(2):194-200. doi: 10.1016/j.clim.2011.10.006. Epub 2011 Nov 4.

PMID:
22122798
50.

Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition.

van Cruijsen H, Oosterhoff D, Lindenberg JJ, Lougheed SM, Fehres C, Weijers K, van Boerdonk R, Giaccone G, Scheper RJ, Hoekman K, de Gruijl TD.

Immunotherapy. 2011 Sep;3(9):1051-61. doi: 10.2217/imt.11.107.

PMID:
21913828

Supplemental Content

Loading ...
Support Center